EA
SAGE

Emerald Acquisition’s Sage Therapeutics SAGE Stock Holding History

Emerald Acquisition’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$280K Buy
+6,091
New +$248K ﹤0.01% 2616

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Emerald Acquisition's SAGE Position: Q3 2016 in Review

Emerald Acquisition opened a new position in Sage Therapeutics (SAGE) in Q3 2016: 6,091 shares worth $280K. The stake represents ﹤0.01% of the portfolio and ranks #2616 among its holdings.

152 funds tracked by Wall St. Rank hold SAGE as of Q3 2016.

  • Emerald Acquisition held 6,091 shares of Sage Therapeutics worth $280K as of Q3 2016.
  • Sage Therapeutics was a new Emerald Acquisition position in Q3 2016.
  • Sage Therapeutics made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2616 holding.
  • 152 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.